Canada markets closed

Nanalysis Scientific Corp. (NSCI.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
1.4100-0.0600 (-4.08%)
At close: 03:35PM EST
Sign in to post a message.
  • M
    Mark
    If you haven't you should listen to the conference call from yesterday. Strong quarter despite delivery issues for key parts for the lead product and the new production area not quite finished yet. Other products picked up the slack and gave them 100% YOY growth. Issues should be corrected early next year and you can fold in anywhere from 15 to 30 100mh instruments which would add anywhere from $2M to $4M PER QUARTER to earnings. Analysts on the call clearly impressed and the company giving aggressive guidance for the fourth quarter: 'Pipeline extensive and growing'. Solid performance under trying circumstances and a clear path to profitability next year.
  • M
    Michael
    From rowdyrhino on ceo.ca:
    Deal is expected to finalize mid-Dec, so maybe it contributes to Q4 in a small way
    35 of 40 K-Prime personnel are sales
    - K-Prime is a preferred vendor with 40% of Nanalysis target customers, speeding up purchasing from those customers
    - Seasonality of K-Prime with strong Q4 is similar to Nanalysis, though not as severe because K-Prime sells small consumables that are recurring throughout the year
    - K-Prime has a very strong pharma rolodex, and Nanalysis penetration of pharma is low
    - K-Prime has NOT been a reseller of Nanalysis products because Nanalysis was going to give an exclusive North America deal to one sales organization, and there were several under consideration. So now K-Prime sales people will fly to Calgary to get trained to sell Nanalysis hardware
    - Analysts are pleased with this acquisition, we will likely see an upward price target revision from them post Nov 18 conference call
    - K-Prime + Nanalysis = Leasing in 2022 for NMR
    - Leasing will speed up sales cycle
    - Leasing will make it easier for customers who have difficult capital expense requirements to acquire the NMR devices
    - Leasing will create recurring revenue because when the lease is up the customer will likely replace it with a newer model
    - Leasing enables expensing the NMR devices quicker against taxes, saving companies cash on taxes up front
    Three big benefits of K-Prime acquisition

    K-Prime rolodex and customer relationships
    Leasing
    Possible mega-contract already in the works where K-Prime sells a large number of Nanalysis devices in one deal with a single customer
    Discussion channel for # on CEO.CA, an investment chat community for Canada's small cap markets
    Discussion channel for # on CEO.CA, an investment chat community for Canada's small cap markets
    ceo.ca
  • N
    Naveed
    bought a small position into this. i like their tech, and the ability to disrupt an industry that's just not flexible enough to meet the needs of the market. I love that they have a great balance sheet, are cash flow positive and are now in a growth phase that includes M&A as well as product improvement.
    GLTA
  • M
    Mark
    Nanalysis has filed to repurchase 5% of its own stock. I've never seen a company this size do this and it appears to be a robust vote of confidence on their future cash flow and upcoming earnings. WOW is all I can say.

    CALGARY, AB, Oct. 21, 2021 /CNW/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), is pleased to announce that it has received conditional acceptance from the TSX Venture Exchange to make a Normal Course Issuer Bid ("NCIB") to purchase for cancellation, during the 12-month period starting October 25, 2021, up to 3,844,081 of the Common Shares, representing 5% of the Common Shares outstanding as of October 25, 2021. The program will end on October 24, 2022, the maximum amount of Common Shares is purchased before then or Nanalysis provides earlier notice of termination.
  • M
    Michael
    Solid merger. Less than 1x sales. Well done.
  • M
    Michael
    Research Capital raised their price target to $2.20.

    We view the acquisition of KPrime as a synergistic transaction since it should not only expand NSCI’s sales channels through KPrime’s sales team and existing clients, but also enable KPrime to gain access to NSCI’s existing customer base,” Ma said. “The KPrime transaction should also be financially accretive as its business has been profitable.”
  • T
    Tyler Goldstein
    another green day is always good.

    good industry and undervalued still. worth purchasing
  • L
    Lindsay
    Everyone needs to see the latest presentation from Nanalysis - especially the Q&A section.

    https://youtu.be/4MSj5Y0YQuc
  • M
    Michael
    Another analyst initiating coverage today. Research Capital, speculative buy at $1.90 target. Conservative revenue numbers.
  • K
    Kay
    Echelon Wealth Partners initiates coverage. Keep building little by little :)
    $2.85 price target is quite interesting.
  • R
    Rocko
    great green day today!! keep it going
  • M
    Mark
    Great news indeed.

    What's also encouraging is their guidance. To say that they expect continued growth throughout 2021 is extremely positive and to have stated they will be profitable for this quarter. This should change the valuation going forward and it's just a question of the story getting out.
  • M
    Mark
    Still not enough interest in this story for all the usual reasons.

    No analyst coverage, small market cap, and a technology that folks don't intuitively get. People understand what an MRI is but not what an NMR is when they are actually the same tech. But the facts speak for themselves: revenue up >100% year over year; company has swung from a loss to a profit; large order backlog; and an acquisition plan that will be accretive to the bottom line.

    It's a classic growth story and that is where real money is made. Not a sexy meme stock(unless the meme's show up!) but a solid company that in my opinion is very undervalued. The intermediate term looks good with their scientific instrument play(NMR's are used for research, industry, biotech, etc.) and the long term is the miniaturisation of MRI machines.

    For now we just have to wait until the word gets out. Personally I don't find stocks like this often, and when I do I go all in. That is the case here and look forward to watching this little seedling grow into an oak.
  • M
    Michael
    According to yahoo, earnings release tomorrow.
  • N
    Normand
    NSCI revenue up 120% from Q2 2020… See below.
  • M
    Malcolm
    Yes, could be a winner. Earnings soon.
  • R
    Rocko
    revenue and assets have been growing so far, good sign. Also YTD chart is looking strong as well.

    need more eyes on this stock.
  • F
    F
    What’s happening?
  • A
    Arnold
    3.000 @ .52. Nice company with beautiful products. At the beginning of commercialization
  • M
    Michael
    I think this is just the beginning of a nice run.